摘要
分别表达了rApxⅠr、ApxⅡr、ApxⅢ、rApxⅣr、Apfa和rOMP 6种重组蛋白,以不同组合分组免疫小鼠,分别以APP1型菌(5×109CFU)和APP7型菌(1×1011CFU)进行攻毒。结果显示,试验Ⅱ组(rApxⅠ+rApxⅡ+rApxⅢ+rOMP)的APXⅠ抗体水平、细胞免疫水平及对APP1和APP7型菌的保护效果均显著高于其他各试验组及对照组;试验Ⅰ组(灭活疫苗)、Ⅲ组(rApxⅠ+rApxⅡ+rApxⅢ+rApxⅣ)、Ⅳ组(rApxⅠ+rApxⅡ+rApxⅢ+rApfa)与对照组差异显著,但均显著低于试验Ⅱ组;APXⅠ抗体水平和细胞免疫水平与攻毒保护率呈正相关。证实rApxⅠ+rApxⅡ+rApxⅢ+rOMP组免疫效果最好,可对2个血清型APP的攻击提供有效保护。
With recombinant proteins rApx Ⅰ , rApx Ⅱ , rApx Ⅲ , rApx Ⅳ, rApfa and rOMP against PCP, the BALB/c mice were vaccinated on day 0,14 and 28, respectively. In the vaccinated mice antibody titers were examined every week, and T lymphocyte proliferation and IL-2 production were examined 13, 27 and 34 days post-vaccination（PV）. The vaccinated mice were challenged intranasally with serotype 1 （5×10^9CFU） and serotype 7（1× 10^11CFU） of Actinobacillus pleuropneurnoniae 35 day PV, respectively. In the experimental group Ⅱ （rApx Ⅰ ＋rApx Ⅱ ＋ rApxⅢ trOMP）, the antibody levels against Apx Ⅰ , T lymphocytes proliferation, IL-2 production, and the protective rates against the above 2 serotypes were significantly higher than those in the experimental groups Ⅰ （inactived vaccine）, Ⅲ （rApx Ⅰ ＋rApxⅡ＋ rApxⅢ ＋rApxⅣ） and Ⅳ（rApxⅠ ＋rApxⅡ ＋rApxⅢ ＋rApfa）, as well as the control. Humoral immunity, cellular immunity and protective efficacy in a low level in the experimental groups Ⅰ , Ⅲ and Ⅳ showed that both humoral immunity and cellular immunity had a positive correlation to protective efficacy. The results revealed that the recombinant subunit vaccine containing rApx Ⅰ ＋rApx Ⅱ ＋rApxⅢ ＋rOMP provides significant cross protection by simultaneously stimulating both humoral immunity and cellular immunity.
出处
《中国兽医科学》
CAS
CSCD
北大核心
2006年第12期955-960,共6页
Chinese Veterinary Science
